skip to Main Content

Free Newsletter: Actionable insight every morning for the self-directed investor. Find out more


Another day of slim pickings in terms of corporate announcements, but there’s a drug testing update from AstraZeneca that is unlikely to provide much of a lift for investors. The company’s Terranova trial for a chronic obstructive pulmonary disease therapy has failed to deliver a statistically significant benefit. Markets are already looking gloomy with the Eurozone confusion – this will do nothing to lift the mood for AstraZeneca.

Telford Homes

A chipper set of full year results in from another housebuilder, this time Telford Homes. Revenues up around 10%, 4,000 builds in the pipeline and an 8% increase in the dividend payout. As we’ve noted before, there seems to be something of a mismatch in terms of profitability of the housebuilders versus the generous government subsidies which are being applied and the fact that despite a wavering consumer economy, house prices continue to rise. How this maps out once interest rates increase is perhaps the proverbial elephant in the room.

De La Rue

Full year results from De La Rue this morning, the secure printer who withdrew their bid to make the post-Brexit UK passports – the contract has ironically gone to a French rival. Earnings per share are down on the figure posted a year ago, but have still come in ahead of expectations. Most critically perhaps, the strong order book means that the outlook for the next financial year remains robust.

Become a better investor with SharePad Designed to give you the confidence to pick your own investments, Sharepad gives you access to a wealth of information on UK, US & European stocks. Find out more

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.


Back To Top